Viatris (VTRS) Stock Price, News & Analysis

Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Key Stats

• Today's Range: $8.26 to $8.44
• 50-Day Range: $7.26 to $11.48
• 52-Week Range: $6.85 to $13.55
• Volume: 5.84 million shs
• Average Volume: 9.95 million shs
• Market Capitalization: $10.03 billion
• P/E Ratio: N/A
• Dividend Yield: 5.71%
• Price Target: $10.50
• Consensus Rating: Reduce

Viatris Stock Analysis - MarketRank™

Viatris scored higher than 37% of companies evaluated by MarketBeat, and ranked 572nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Viatris has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.

Amount of Analyst Coverage

Viatris has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -4.10%

Earnings Growth

Earnings for Viatris are expected to decrease by -4.10% in the coming year, from $2.68 to $2.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viatris is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viatris is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viatris has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.96% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viatris has recently increased by 2.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Viatris is a leading dividend payer. It pays a dividend yield of 5.90%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Viatris does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Viatris will have a dividend payout ratio of 18.68% next year. This indicates that Viatris will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.96% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Viatris has recently increased by 2.57%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.03

News Sentiment

Viatris has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 42 news articles for Viatris this week, compared to 7 articles on an average week.

Search Interest

23 people have searched for VTRS on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Viatris insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Viatris is held by insiders.

Percentage Held by Institutions

79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTRS Stock Analysis - Frequently Asked Questions

How have VTRS shares performed this year?

Viatris' stock was trading at $12.45 on January 1st, 2025. Since then, VTRS shares have decreased by 32.4% and is now trading at $8.42.
View the best growth stocks for 2025 here.

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) posted its quarterly earnings results on Thursday, February, 27th. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.57 by $0.03. The business earned $3.53 billion during the quarter, compared to analysts' expectations of $3.60 billion. Viatris had a negative net margin of 5.87% and a positive trailing twelve-month return on equity of 16.46%.
Read the conference call transcript.

Is Viatris doing a stock buyback?

Viatris' board initiated a stock buyback program on Wednesday, February 28th 2024, which permits the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6.7% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

Who are Viatris' major shareholders?

Viatris' top institutional shareholders include Bank of New York Mellon Corp (0.87%), Rhumbline Advisers (0.27%), Sumitomo Mitsui Trust Group Inc. (0.22%) and Robeco Institutional Asset Management B.V. (0.18%). Insiders that own company stock include Rajiv Malik, Anthony Mauro, Paul Campbell, Harry Korman, Brian Roman, Xiangyang (Sean) Ni, Dillon Joellen Lyons, Andrew Cuneo, Der Meer Mohr Pauline Van and Menassie Taddese.
View institutional ownership trends.

How do I buy shares of Viatris?

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viatris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viatris investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Tesla (TSLA) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 2/27/2025
• Record date for 3/18 Dividend: 3/10/2025
• Ex-Dividend for 3/18 Dividend: 3/10/2025
• Dividend Payable: 3/18/2025
• Today: 4/30/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTRS
• CIK: 1792044
• Web: www.viatris.com
• Phone: (724) 514-1800
• Fax: 724-514-1870
• Employees: 37,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.50
• High Stock Price Target: $13.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +25.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3.13
• P/E Growth: N/A
• Net Income: $54.70 million
• Net Margins: -5.87%
• Pretax Margin: -6.32%
• Return on Equity: 16.46%
• Return on Assets: 7.09%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 1.51
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $14.74 billion
• Price / Sales: 0.68
• Cash Flow: $3.98 per share
• Price / Cash Flow: 2.11
• Book Value: $17.06 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 1,193,689,000
• Free Float: 1,192,041,000
• Market Cap: $10.02 billion
• Optionable: Optionable
• Beta: 0.91